AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain
Completed
- Conditions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT06487065
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 478
- Registration Number
- NCT06485674
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
A Multicenter Cluster Randomized Controlled Study to Evaluate Guideline Adoption Through Lung Cancer Clinical Care Quality Improvement Project (QIP) in Pulmonary and Critical Care Medicine (PCCM) Department
Not yet recruiting
- Conditions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1728
- Registration Number
- NCT06484972
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
Recruiting
- Conditions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT06472310
- Locations
- 🇷🇺
Research Site, Yekaterinburg, Russian Federation
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06473779
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 790
- Registration Number
- NCT06471257
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 620
- Registration Number
- NCT06467357
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 84
- Registration Number
- NCT06469151
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT06465810
- Locations
- 🇬🇧
Research Site, London, United Kingdom
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06465485
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
© Copyright 2024. All Rights Reserved by MedPath